MedCentralSuzetrigine’s Approval Signals a Shift in Non-Opioid Pain Management

The FDA’s recent approval of suzetrigine (Journavx), a novel NaV1.8 inhibitor, marks a significant advancement in non-opioid pain management. Suzetrigine is designed to treat moderate-to-severe acute pain and offers a new therapeutic option for patients and physicians seeking alternatives to opioids. This approval is supported by robust clinical trial data demonstrating its efficacy and safety

Key Points:

• FDA Approval: Suzetrigine (Journavx) was approved by the FDA on January 30, 2025, as the first novel drug class for acute pain in more than two decades.
• Mechanism of Action: Suzetrigine selectively inhibits NaV1.8, a voltage-gated sodium channel involved in pain signal transmission, providing pain relief without the potential for misuse.
• Clinical Trials: Two Phase 3 trials demonstrated significant pain relief with suzetrigine compared to placebo in patients undergoing abdominoplasty and bunionectomy, though it did not outperform hydrocodone bitartrate/acetaminophen (HB/APAP).
• Safety Profile: Suzetrigine was generally well tolerated, with lower adverse event rates compared to HB/APAP and no serious adverse events related to the drug.
• NOPAIN Act: The NOPAIN Act, effective January 1, 2025, mandates Medicare to provide additional payments for FDA-approved non-opioid pain therapies, potentially increasing suzetrigine’s accessibility.
• Patient Feedback: In a single-arm safety study, 83.2% of participants rated suzetrigine as good, very good, or excellent for pain relief.

The opioid crisis continues to shape pain management, with overdose-related deaths still alarmingly high despite a 12% drop in prescription opioid–related deaths from 2021 to 2022. (PharmaVoice)

More in Pain Management